Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
Clinical trial NCT03084237 · COMPLETED
Trial details
- NCT number
- NCT03084237
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2018-11-23
- Enrollment
- 652
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.